LB
Leaps by Bayer
Venture CapitalActiveLeaps by Bayer is spearheading a movement to make paradigm-shifting advances in the life sciences.
11
Investments
4
Exits
—
AUM
36.4%
Exit Rate
Get contact info, warm intros & fit scores
Sign up to unlock emails, Signal intro paths, and personalized fit analysis for Leaps by Bayer.
Investment Thesis & Strategy
Leaps by Bayer invests in various stages of life sciences companies with the goal of making paradigm-shifting advances. They focus on companies with the potential for significant impact in the life sciences sector.
Investment Activity
Deals per year over the last 5 years
1
20172
20184
20190
20205
2021Portfolio Companies
Selected investments from their portfolio of 11 companies
T
Tessera Therapeutics
Biotech · Series B, 2021
C
Cellino
Biotech · Series A, 2021
P
Pairwise
Biotech · Series B, 2021
A
Atai Life Sciences
Biotech · Growth, 2021
I
Inari Agriculture
Biotech · Series C+, 2021
V
Vividion Therapeutics
Biotech · Series B, 2019
S
Sana Biotechnology
Biotech · Series B, 2019
I
Insitro
Biotech · Series B, 2019
C
Century Therapeutics
Biotech · Series A, 2019
R
Rallybio
Biotech · Series A, 2018
Z
Zymergen
Biotech · Seed, 2018
B
BlueRock Therapeutics
Biotech · Series A, 2017
Notable Exits
CompanyTypeYearValue / Acquirer
CellinoAcquisition2024—
Vividion TherapeuticsAcquisition2021$1.5B
BlueRock TherapeuticsAcquisition2019$1B
IgnytaAcquisition2017$1.7B
Frequently Asked Questions
Leaps by Bayer focuses on Series A, Series B, Series C+ stage investments.
Related Investors
Bessemer Venture Partners
Redwood City, United States · 971 deals
Threshold
Menlo Park, United States · 841 deals
Lightspeed Venture Partners
Menlo Park, United States · 839 deals
Index Ventures
San Francisco, United States · 827 deals
Andreessen Horowitz
Menlo Park, United States · 826 deals
Goldman Sachs
New York, United States · 780 deals